allodepleted t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00710892)
Timeline
Indications
Mechanism of action
- Unspecified targetTissue restoration
Tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- allodepleted t cells
- donor t-lymphocytes depleted ex vivo of host alloreactive t-cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01794299 | Phase 2 | Mar 1, 2013 | Kiadis Pharma, University of Montreal |
| NCT00710892 | Phase 1 | Dec 1, 2008 | Baylor University, Methodist Cancer Center, Houston, Texas |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Kiadis Pharma | For profit | 1 | 1 | 1 | 2013 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Montreal | Academic/Hospital | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1